Vein Graft Patency Rates With Aspirin Plus Clopidogrel Following Coronary Artery Bypass Grafting

Area of Science:

• Cardiovascular Surgery
• Pharmacology
• Clinical Evidence Synthesis

Background:

• Coronary Artery Bypass Grafting (CABG) is a common procedure to improve blood flow to the heart.
• Maintaining the patency of vein grafts after CABG is crucial for long-term patient outcomes.
• Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is often considered post-CABG.

Purpose of the Study:

• To evaluate the efficacy of dual antiplatelet therapy (aspirin plus clopidogrel) versus single antiplatelet therapy (aspirin alone) in improving vein graft patency after Coronary Artery Bypass Grafting (CABG).
• To synthesize the best available evidence regarding the impact of DAPT on graft patency, mortality, and adverse vascular events post-CABG.

Main Methods:

• A structured best evidence topic search was conducted.
• Literature search identified 165 relevant papers.
• Five papers were selected as the highest quality evidence to address the clinical question.

Main Results:

• Analysis of the best evidence demonstrated no significant difference in vein graft patency rates between patients receiving aspirin plus clopidogrel and those receiving aspirin alone.
• No statistically significant differences were observed in mortality rates between the two antiplatelet therapy groups.
• Adverse bleeding-related outcomes and composite vascular events did not differ significantly between the treatment groups.

Conclusions:

• Postoperative dual antiplatelet therapy with aspirin and clopidogrel does not appear to offer superior vein graft patency compared to aspirin alone in patients following Coronary Artery Bypass Grafting.
• The use of aspirin plus clopidogrel post-CABG did not show an advantage in reducing mortality, bleeding complications, or other vascular events in the analyzed studies.